A key stepping stone towards introducing the first vaccine against the Aids virus was announced yesterday.

The decision by the United States Food and Drug Administration to approve Phase Three trials of the vaccine was described as ''a milestone'' in the fight against Aids.

Phase Three trials are designed to test the effectiveness of a drug and usually involve large numbers of patients.

If the trials prove successful, it will pave the way for the anti-HIV vaccine, Aidsvax, to be licensed and go on the market. The trials should also help the development of other similar drugs.

Inoculations of Aidsvax will begin this month and could involve 5000 volunteers in major cities across America.

The vaccine's creator, the pharmaceutical company VaxGen, hopes to hold a second trial in Thailand later this year.

Mr Derek Bodell, director of the National Aids Trust in Britain, said: ''This is a milestone in the fight against Aids, and also a crucial psychological hurdle.

''With over 16,000 people being infected with HIV every day and over 30 million people now living with the virus (worldwide) an effective vaccine is something the world desperately needs.''